Resmetirom in Patients With MASH and HFpEF
NCT07830758
This study is recruiting at 5 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
This Phase 1b multicenter randomized double-blind placebo-controlled study evaluates the safety, tolerability and hepatic pharmacodynamic effects of resmetirom in adults with metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF). Participants are randomized 2:1 to resmetirom or placebo for 24 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Heart Failure With Preserved Ejection Fraction (HFPEF)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Madrigal Pharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- October 16, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Arizona Clinical Trials · Peoria, AZ
California · 1
- FOMAT - Clinicas Mi Salud · Oxnard, CA
Florida · 3
- Covenant Metabolic Specialist · Fort Myers, FL
- Covenant Metabolic Specialist · Riverview, FL
- Covenant Metabolic Specialist · University Park, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.